
## GD GUNDERSON DETTMER



# Keith J. Scherer

**PARTNER Boston**P +1 617 648 9231

Keith leverages his deep experience and technical expertise to help companies and funds achieve their business objectives with a client-focused, practical, and commercial approach.

Keith is a Public Offerings/Public Companies partner in Gunderson Dettmer's Boston office, and his practice focuses on three areas:

- Advising public companies on corporate and securities topics, including public and private debt and equity financings, strategic transactions, corporate governance and ongoing public reporting and compliance
- Counseling founders and late-stage emerging growth companies exploring a
  possible IPO and preparing companies to go public and for post-IPO matters
- Representing venture capital funds on investments in public companies, including private investments in public equity (PIPEs) and registered direct offerings, and

advising venture capital funds with respect to their sales and distributions of public company securities and IPOs, mergers, acquisitions and other strategic transactions involving their portfolio companies

Across all his work, Keith brings a practical and problem-solving mindset, leveraging his experience representing public and late-stage private companies and funds in wide variety of ongoing and transactional matters. He fosters long-term relationships with his clients by understanding the broader business objectives beyond the immediate deal and by prioritizing responsiveness throughout the representation. Keith works across nearly all industries and supports efficiency in transactions by bringing industry best practices into every deal.

Keith's recent representative matters include:

- Flywire Corporation, a global payments enablement and software company, in its \$250 million IPO and \$272 million follow-on public offering
- Synchronoss Technologies, a global cloud platform company, in multiple PIPEs and public offerings of equity and debt (totaling over \$570 million)
- Schooner Capital, a growth capital fund based in Boston, in the \$130 million PIPE offering by Cartesian Therapeutics, a public clinical-stage biopharma company
- TCGx, a San Francisco-based venture capital firm, in the \$185 million PIPE offering by Avalo Therapeutics, a public clinical-stage biotechnology company
- Oklo Inc., an advanced fission technology and nuclear fuel recycling company, in its \$850 million, go public deSPAC transaction with AltC Acquisition Corp.
- Qlik Technologies in its take private sale to Thoma Bravo for \$3 billion and Affinivax in its acquisition by GSK for up to \$3.3 billion

Having represented issuers and investors in over \$1 billion of PIPE transactions, Keith is a leading advisor in highly structured PIPE transactions. Recently, Keith was part of a national coalition of attorneys, investors, issuers and bank placement agents that created a library of model legal documents for PIPE financings. The task force created the model library to establish industry norms and reduce transaction costs and time.

Keith is the father of two and enjoys hiking, traveling and managing his fantasy football teams.

Keith is a graduate of Emory University School of Law and American University.

### Credentials

### **EDUCATION**

- Emory University School of Law, J.D.
   Order of the Coif
   Honors
- · American University, B.A., Psychology and Justice

### **BAR ADMISSIONS**

- Massachusetts
- New York

### **Focus Areas**

Corporate Governance & Strategy
Initial Public Offerings (IPOs) & Direct Listings
Mergers & Acquisitions
Public Companies/Public Offerings
Seed, Venture and Growth Financings

# Related News & Insights

### **CLIENT NEWS**

Gunderson Dettmer Represents The Column Group in Surrozen's \$175 Million Oversubscribed Private Placement

#### **CLIENT NEWS**

Flywire Announces Acquisition of Sertifi

#### **CLIENT NEWS**

Flywire Announces \$256 Million Follow-on Public Offering

### **CLIENT NEWS**

Oklo to Go Public with AltC Acquisition Corp Merger

**CLIENT NEWS** 

Alimera Sciences Acquires Commercial Rights to YUTIQ® in the U.S.

**CLIENT NEWS** 

GSK Completes Acquisition of Gunderson Dettmer Client Affinivax

**CLIENT NEWS** 

Biopharmaceutical Company Affinivax Announces \$3.3B Acquisition by GSK

FIRM NEWS

Gunderson Dettmer Announces 15 New Elected Partners in Record-Setting Partner Class

**CLIENT NEWS** 

Gunderson Dettmer Advises Synchronoss on Two Public Offerings and Private Placement

**CLIENT NEWS** 

Barkbox Announces it will Become a Public Company through Merger with Northern Star Acquisition Corporation

**CLIENT NEWS** 

Gunderson Dettmer Advises Flywire on its Initial Public Offering

**INSIGHTS** 

Direct Listings Gain Traction as IPO Alternative: SEC Approves Nasdaq Rule Change to Permit Capital Raising in Direct Listings

**CLIENT NEWS** 

TScan Therapeutics Raises \$100M Series C Financing